Scilex (SCLX) Competitors $18.08 +0.71 (+4.09%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$18.42 +0.34 (+1.85%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCLX vs. ATXS, FULC, PRTA, OLMA, CYRX, CAPR, HUMA, KOD, AURA, and ARCTShould you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Astria Therapeutics (ATXS), Fulcrum Therapeutics (FULC), Prothena (PRTA), Olema Pharmaceuticals (OLMA), CryoPort (CYRX), Capricor Therapeutics (CAPR), Humacyte (HUMA), Kodiak Sciences (KOD), Aura Biosciences (AURA), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Scilex vs. Its Competitors Astria Therapeutics Fulcrum Therapeutics Prothena Olema Pharmaceuticals CryoPort Capricor Therapeutics Humacyte Kodiak Sciences Aura Biosciences Arcturus Therapeutics Astria Therapeutics (NASDAQ:ATXS) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends. Which has preferable valuation and earnings, ATXS or SCLX? Scilex has higher revenue and earnings than Astria Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$94.26M-$2.01-3.41Scilex$56.59M2.22-$72.81M-$29.02-0.62 Do institutionals & insiders hold more shares of ATXS or SCLX? 99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 4.5% of Astria Therapeutics shares are held by company insiders. Comparatively, 7.9% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, ATXS or SCLX? Astria Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Does the media favor ATXS or SCLX? In the previous week, Astria Therapeutics had 20 more articles in the media than Scilex. MarketBeat recorded 26 mentions for Astria Therapeutics and 6 mentions for Scilex. Astria Therapeutics' average media sentiment score of 0.99 beat Scilex's score of -0.03 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ATXS or SCLX more profitable? Astria Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -179.12%. Scilex's return on equity of 0.00% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -56.39% -36.08% Scilex -179.12%N/A -109.95% Do analysts recommend ATXS or SCLX? Astria Therapeutics presently has a consensus price target of $29.00, suggesting a potential upside of 323.36%. Scilex has a consensus price target of $455.00, suggesting a potential upside of 2,416.59%. Given Scilex's higher possible upside, analysts clearly believe Scilex is more favorable than Astria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Scilex 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryAstria Therapeutics beats Scilex on 9 of the 16 factors compared between the two stocks. Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCLX vs. The Competition Export to ExcelMetricScilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.82M$3.09B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-0.6220.3830.5825.12Price / Sales2.22362.40464.45115.80Price / CashN/A42.3037.4059.05Price / Book-0.518.659.096.18Net Income-$72.81M-$54.65M$3.25B$264.89M7 Day Performance15.01%6.58%7.32%4.18%1 Month Performance158.29%7.54%5.42%1.99%1 Year Performance-58.00%13.73%30.66%24.22% Scilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCLXScilex2.2 of 5 stars$18.08+4.1%$455.00+2,416.6%-58.3%$120.82M$56.59M-0.6280News CoverageEarnings ReportATXSAstria Therapeutics2.7101 of 5 stars$6.89+5.0%$29.00+320.9%-38.1%$370.21MN/A-3.6830Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics1.501 of 5 stars$6.96+1.9%$7.57+8.8%-29.6%$369.45M$80M0.00100PRTAProthena3.5343 of 5 stars$6.94+1.9%$31.50+353.9%-60.5%$366.56M$135.16M-3.34130OLMAOlema Pharmaceuticals1.6374 of 5 stars$5.41+1.5%$24.50+352.9%-55.5%$364.68MN/A0.0070News CoverageEarnings ReportAnalyst ForecastCYRXCryoPort3.8324 of 5 stars$7.16-1.5%$10.63+48.4%-4.1%$364.50M$228.38M-3.061,186CAPRCapricor Therapeutics3.0508 of 5 stars$7.68-2.8%$22.56+193.7%+104.1%$360.85M$22.27M-5.41101Trending NewsEarnings ReportAnalyst RevisionHUMAHumacyte1.9979 of 5 stars$2.26-0.9%$11.71+418.3%-69.4%$353.67M$1.57M0.00150News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionKODKodiak Sciences2.4318 of 5 stars$7.31+9.9%$9.00+23.1%+308.1%$350.88MN/A0.0090News CoverageEarnings ReportAnalyst UpgradeAURAAura Biosciences2.3447 of 5 stars$6.61-1.9%$22.00+232.8%-17.8%$338.81MN/A0.0050News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionARCTArcturus Therapeutics2.8789 of 5 stars$12.20-0.8%$54.00+342.6%-3.8%$333.58M$152.31M-4.82180News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ATXS Alternatives FULC Alternatives PRTA Alternatives OLMA Alternatives CYRX Alternatives CAPR Alternatives HUMA Alternatives KOD Alternatives AURA Alternatives ARCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCLX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access